Open AccessTreatment with the vascular disruptive agent OXi4503 induces an immediate and widespread epithelial to mesenchymal transition in the surviving tumor
Author(s) -
Fifis Theodora,
Nguyen Linh,
MalcontentiWilson Cathy,
Chan Lie Sam,
Nunes Costa Patricia Luiza,
Daruwalla Jurstine,
Nikfarjam Mehrdad,
Muralidharan Vijayaragavan,
Waltham Mark,
Thompson Erik W.,
Christophi Christopher
Publication year - 2013
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.109
Subject(s) - epithelial–mesenchymal transition , downregulation and upregulation , cancer research , metastasis , vascular endothelial growth factor , vimentin , colorectal cancer , in vivo , tumor progression , hepatocyte growth factor , medicine , pathology , biology , cancer , receptor , immunohistochemistry , microbiology and biotechnology , vegf receptors , gene , biochemistry
Epithelial to mesenchymal transition (EMT) is considered an important mechanism in tumor resistance to drug treatments; however, in vivo observation of this process has been limited. In this study we demonstrated an immediate and widespread EMT involving all surviving tumor cells following treatment of a mouse model of colorectal liver metastases with the vascular disruptive agent OXi4503. EMT was characterized by significant downregulation of E‐cadherin, relocation and nuclear accumulation of β‐catenin as well as significant upregulation of ZEB1 and vimentin. Concomitantly, significant temporal upregulation in hypoxia and the pro‐angiogenic growth factors hypoxia‐inducible factor 1‐alpha, hepatocyte growth factor, vascular endothelial growth factor and transforming growth factor‐beta were seen within the surviving tumor. The process of EMT was transient and by 5 days after treatment tumor cell reversion to epithelial morphology was evident. This reversal, termed mesenchymal to epithelial transition (MET) is a process implicated in the development of new metastases but has not been observed in vivo histologically. Similar EMT changes were observed in response to other antitumor treatments including chemotherapy, thermal ablation, and antiangiogenic treatments in our mouse colorectal metastasis model and in a murine orthotopic breast cancer model after OXi4503 treatment. These results suggest that EMT may be an early mechanism adopted by tumors in response to injury and hypoxic stress, such that inhibition of EMT in combination with other therapies could play a significant role in future cancer therapy.